A Unique Approach
to Immunology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.
Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with severe inflammatory and autoimmune diseases.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
Alpine’s Pipeline
We have a diverse pipeline across inflammatory/autoimmune disease and immuno-oncology. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Acazicolcept (ALPN-101)
Dual CD28/ICOS Costimulation Antagonist
Autoimmune Diseases
ALPN-303
Dual BAFF/APRIL B cell cytokine antagonist
Autoimmune Diseases
Alpine Immune Sciences News Releases
- Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx ConferenceSEATTLE --(BUSINESS WIRE)--Nov. 22, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the 5 th
- Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsSEATTLE --(BUSINESS WIRE)--Nov. 14, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third
- Alpine Immune Sciences to Report Third Quarter 2022 Financial ResultsSEATTLE --(BUSINESS WIRE)--Nov. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results
